Etomidate Analogs: State of Development

Abstract

As an anesthetic agent, etomidate provides profound hemodynamic stability, superior to propofol even when it is dose reduced. However, its use has been curtailed due to concerns regarding adrenal cortical suppression demonstrated clinically in the setting of prolonged infusion for sedation in the intensive care unit. In addition, etomidate reproducibly results in significant myoclonus when employed in the absence of other pharmacology. Recently, utilizing both pharmacokinetic and pharmacodynamic considerations, a number of etomidate analogs have been developed that retain the favorable properties of their parent agent, including rapid onset of hypnosis and rapid recovery, amnesia, and cardiovascular stability, but do not result in inhibition of steroidogenesis. A few of these analogs have now entered clinical trials and are poised to transform acute care and anesthesia for critically ill patients.

Keywords

Etomidate analogs / Adrenal suppression / Drug design / ET-26 / ET-42

References

[1] Swerdlow B. Patient Safety Matters with Use of Propofol in Critically Ill Patients. Cardiovasc. Sci. 2025, 2, 10013. DOI:10.70322/cvs.2025.10013

[2] Chen Y, Wu L, Lang B, Zhang W, Chen S. Recent progress in the development of etomidate analogues. Front. Pharmacol. 2025, 16, 1614865. DOI:10.3389/fphar.2025.1614865

[3] Urman R, Malapero R, Zaccagnino M, Brovman E, Kaye A. Etomidate derivatives: Novel pharmaceutical agents in anesthesia. J. Anaesthesiol. Clin. Pharmacol. 2017, 33, 429. DOI:10.4103/0970—9185.222521

[4] Kotani Y, Russotto V. Induction Agents for Tracheal Intubation in Critically Ill Patients. Crit. Care Med. 2025, 53, e173-e181. DOI:10.1097/CCM.0000000000006506

[5] Ladha S, Prakash A. CON: Propofol Is Better Than Etomidate for Induction in Cardiac Surgical Patients. J. Card. Crit. Care TSS 2021, 5, 72-74. DOI:10.1055/s—0041—1728957

[6] Valk BI, Struys MMRF. Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics. Clin. Pharmacokinet. 2021, 60, 1253-1269. DOI:10.1007/s40262—021—01038—6

[7] Cagliani JA, Ruhemann A, Molmenti E, Smith C, Coppa G, Barrera R. Association between Etomidate Use for Rapid Sequence Intubation and Adrenal Insufficiency in Sepsis. Cureus 2021, 13, e13445. DOI:10.7759/cureus.13445

[8] Upadhye S, Cyganik O. Is Single—Dose Etomidate Induction Safe in Emergency Intubation of Critically Ill Patients? Ann. Emerg. Med. 2016, 67, 399-400. DOI:10.1016/j.annemergmed.2015.10.006

[9] Sarda BG, Raipure AM, Ruparel DH. Serum Cortisol Levels with Etomidate Induction. Anesth. Essays Res. 2021, 15, 312-315. DOI:10.4103/aer.aer_118_21

[10] Komatsu R, You J, Rajan S, Kasuya Y, Sessler DI, Turan A. Steroid administration after anaesthetic induction with etomidate does not reduce in—hospital mortality or cardiovascular morbidity after non—cardiac surgery. Br. J. Anaesth. 2018, 120, 501-508. DOI:10.1016/j.bja.2017.11.079

[11] Gu WJ, Wang F, Tang L, Liu JC. Single—Dose Etomidate Does Not Increase Mortality in Patients with Sepsis. Chest 2015, 147, 335-346. DOI:10.1378/chest.14—1012

[12] Dalia AA, Raines DE. Etomidate and Adrenocortical Suppression: Should We Take the Concerns to Heart? J. Cardiothorac. Vasc. Anesth. 2021, 35, 1086-1088. DOI:10.1053/j.jvca.2021.01.034

[13] Chittoria K, Sharma A. The novel etomidate analog: A potential induction agent. Saudi J. Anaesth. 2025, 19, 614-616. DOI:10.4103/sja.sja_503_25

[14] Jung JH, Hyun B, Lee J, Koh DH, Kim JH, Park SW. Neurologic Safety of Etomidate—Based Sedation during Upper Endoscopy in Patients with Liver Cirrhosis Compared with Propofol: A Double—Blind, Randomized Controlled Trial. J. Clin. Med. 2020, 9, 2424. DOI:10.3390/jcm9082424

[15] Luan HF, Zhao ZB, Feng JY, Cui JZ, Zhang XB, Zhu P, et al. Prevention of etomidate—induced myoclonus during anesthetic induction by pretreatment with dexmedetomidine. Braz. J. Med. Biol. Res. 2015, 48, 186-190. DOI:10.1590/1414—431x20144100

[16] Geng D, Li Y, Wang C, Ren B, Wang H, Wu C, et al. Optimization, and in vitro and in vivo evaluation of etomidate intravenous lipid emulsion. Drug Deliv. 2021, 28, 873-883. DOI:10.1080/10717544.2021.1917729

[17] Zhang KD, Wang LY, Zhang DX, Zhang ZH, Wang HL. Comparison of the Effectiveness of Various Drug Interventions to Prevent Etomidate—Induced Myoclonus: A Bayesian Network Meta—Analysis. Front. Med. 2022, 9, 799156. DOI:10.3389/fmed.2022.799156

[18] McGrath M, Raines DE. Anesthetic Drug Discovery and Development: A Case Study of Novel Etomidate Analogs. Methods Enzymol. 2018, 603, 153-169. DOI:10.1016/bs.mie.2018.01.026

[19] Forman SA, Warner DS. Clinical and Molecular Pharmacology of Etomidate. Anesthesiology 2011, 114, 695-707. DOI:10.1097/ALN.0b013e3181ff72b5

[20] Zhao Y, Ai W, Zhao J, Yang X, Liu W, Ma Y, et al. From target specificity to metabolic efficiency: Design and optimization of etomidate analogues for potential improvement in postoperative outcomes. Acta Pharm. Sin. B 2026, 16, 2420-2443. DOI:10.1016/j.apsb.2026.01.008

[21] Pejo E, Zhou X, Husain SS, Raines DE. Sedative—hypnotic Binding to 11β—hydroxylase. Anesthesiology 2016, 125, 943-951. DOI:10.1097/ALN.0000000000001304

[22] Deng C, Liu J, Zhang W. Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs. Front. Pharmacol. 2022, 13, 923353. DOI:10.3389/fphar.2022.923353

[23] Sneyd JR, Valk BI. Etomidate and its derivatives: Time to say goodbye? Br. J. Anaesth. 2025, 134, 11-13. DOI:10.1016/j.bja.2024.09.011

[24] Yang J, Kang Y, Wang B, Yang L, Liu J, Zhang W. Metabolite—inactive etomidate analogues alleviating suppression on adrenal function in Beagle dogs. Eur. J. Pharm. Sci. 2017, 99, 343-349. DOI:10.1016/j.ejps.2016.12.041

[25] Yang F, Ye P, Lv W, Li L, Zhao B, van denAnker J, et al. Methoxyethyl Etomidate Hydrochloride (ET—26): A Phase I Clinical Trial Assessing Drug—Drug Interactions in Healthy Subjects. J. Clin. Pharmacol. 2025, 65, 1443-1450. DOI:10.1002/jcph.70071

[26] Jiang X, Yin Q, Deng X, Zhang W, Zhang W, Liu J. Advance of a new etomidate analogue—Methoxyethyl etomidate hydrochloride (ET—26) for anesthesia induction in surgical patients. Anesthesiol. Periop. Sci. 2024, 2, 22. DOI:10.1007/s44254—024—00062—6

[27] Liu X, Song H, Yang J, Zhou C, Kang Y, Yang L, et al. The etomidate analog ET—26 HCl retains superior myocardial performance: Comparisons with etomidate in vivo and in vitro. PLoS ONE 2018, 13, e0190994. DOI:10.1371/journal.pone.0190994

[28] TrialX. A Trial to Evaluate the Efficacy and Safety of Methoxyetomidate Hydrochloride for Injection (ET—26) for the Induction of General Anesthesia in Elective Surgery Subjects. Available online: https://www.trialx.com/clinical—trials/listings/240953/a—trial—to—evaluate—7/ (accessed on 12 June 2026).

[29] Miller TE, Gan TJ. Total Intravenous Anesthesia and Anesthetic Outcomes. J. Cardiothorac. Vasc. Anesth. 2015, 29, S11-S15. DOI:10.1053/j.jvca.2015.01.022

[30] Yin Q, Yang Y, Liu J, Li L, Yang X, Diao L, et al. Phase 1 single—centre placebo— and etomidate—controlled study in healthy volunteers to assess safety, tolerability, clinical effects, and pharmacokinetics of intravenous methoxyethyl etomidate hydrochloride (ET—26). Br. J. Anaesth. 2025, 134, 80-88. DOI:10.1016/j.bja.2024.09.009

[31] Orkaby A, Desai SP. The Death of Sodium Pentothal: The Rise and Fall of an Anesthetic Turned Lethal. J. Hist. Med. Allied Sci. 2021, 76, 294-318. DOI:10.1093/jhmas/jrab016

[32] Xu X, Wei Y, Dong Y, Qiu Y, Mei Z, Wang K, et al. A Novel Etomidate Analog EL—0052 Retains Potent Hypnotic Effect and Stable Hemodynamics without Suppressing Adrenocortical Function. J. Pharmacol. Exp. Ther. 2021, 379, 324-330. DOI:10.1124/jpet.121.000691

[33] Azad I, Khan T, Ahmad N, Khan AR, Akhter Y. Updates on Drug Designing Approach Through Computational Strategies: a Review. Future Sci. OA 2023, 9, FSO862. DOI:10.2144/fsoa—2022—0085